Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilostazol.

E M Sorkin1, A Markham

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|March 9, 1999
PubMed
Summary
This summary is machine-generated.

Cilostazol effectively treats peripheral artery disease by improving walking distance and quality of life. This antiplatelet and vasodilator medication demonstrated superior results compared to pentoxifylline and placebo in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Vascular Medicine

Background:

  • Cilostazol is an antiplatelet agent with vasodilating properties.
  • It is used to treat peripheral artery disease, specifically intermittent claudication.

Purpose of the Study:

  • To evaluate the efficacy and safety of cilostazol in patients with intermittent claudication.
  • To compare cilostazol with pentoxifylline and placebo.

Main Methods:

  • Double-blind, randomized trials were conducted.
  • Patients received cilostazol, pentoxifylline, or placebo.

Main Results:

  • Cilostazol significantly improved pain-free and maximum walking distances compared to placebo.
  • Improvements in physical functioning and quality of life were observed with cilostazol.

Related Experiment Videos

  • Cilostazol showed greater efficacy than pentoxifylline in a 24-week trial.

    • Conclusions:

    • Cilostazol is an effective treatment for intermittent claudication.
    • The drug is well-tolerated, with common side effects including headache and gastrointestinal issues.